GPS Wealth Strategies Group LLC Has $1.27 Million Stake in Johnson & Johnson $JNJ

GPS Wealth Strategies Group LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,326 shares of the company’s stock after selling 357 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Johnson & Johnson were worth $1,272,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in JNJ. Nuveen LLC acquired a new position in Johnson & Johnson during the first quarter worth $1,369,188,000. Pacer Advisors Inc. boosted its holdings in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after purchasing an additional 2,825,626 shares during the last quarter. Assenagon Asset Management S.A. boosted its holdings in Johnson & Johnson by 159.6% during the second quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after purchasing an additional 2,557,388 shares during the last quarter. Kingstone Capital Partners Texas LLC acquired a new stake in Johnson & Johnson in the second quarter valued at $401,420,000. Finally, Dimensional Fund Advisors LP lifted its stake in Johnson & Johnson by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 16,903,105 shares of the company’s stock valued at $2,803,042,000 after acquiring an additional 2,129,612 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Bank of America raised their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Citigroup raised their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. HSBC raised their target price on shares of Johnson & Johnson from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $186.89 on Wednesday. The firm has a 50-day moving average of $183.64 and a 200-day moving average of $168.16. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a market cap of $450.27 billion, a PE ratio of 18.04, a P/E/G ratio of 2.19 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s payout ratio is 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.